NASDAQ:GNPX Genprex (GNPX) Stock Price, News & Analysis $0.84 -0.06 (-7.03%) As of 01/3/2025 05:45 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends About Genprex Stock (NASDAQ:GNPX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genprex alerts:Sign Up Key Stats Today's Range$0.81▼$0.8750-Day Range$0.83▼$2.7452-Week Range$0.28▼$14.40Volume957,169 shsAverage Volume1.08 million shsMarket Capitalization$7.13 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewGenprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Read More… Genprex Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks81st Percentile Overall ScoreGNPX MarketRank™: Genprex scored higher than 81% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGenprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenprex has received no research coverage in the past 90 days.Read more about Genprex's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Genprex are expected to grow in the coming year, from ($5.70) to ($2.71) per share.Price to Book Value per Share RatioGenprex has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.67% of the float of Genprex has been sold short.Short Interest Ratio / Days to CoverGenprex has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genprex has recently increased by 46.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenprex does not currently pay a dividend.Dividend GrowthGenprex does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.78 Percentage of Shares Shorted7.67% of the float of Genprex has been sold short.Short Interest Ratio / Days to CoverGenprex has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genprex has recently increased by 46.53%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News SentimentN/A News SentimentGenprex has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Genprex this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for GNPX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genprex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.47% of the stock of Genprex is held by insiders.Percentage Held by InstitutionsOnly 14.05% of the stock of Genprex is held by institutions.Read more about Genprex's insider trading history. Receive GNPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter. Email Address GNPX Stock News HeadlinesGenprex, Inc. (NASDAQ:GNPX) Short Interest Up 46.5% in DecemberDecember 30, 2024 | americanbankingnews.comGenprex receives Safety Review Committee approval to advance Acclaim-3 trialDecember 17, 2024 | markets.businessinsider.com⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.January 6, 2025 | Behind the Markets (Ad)Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerDecember 16, 2024 | prnewswire.comGenprex signs exclusive license agreement with University of MichiganNovember 20, 2024 | markets.businessinsider.comGenprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung CancerNovember 20, 2024 | prnewswire.comGenprex to present positive preclinical data from Reqorsa Gene Therapy studyNovember 6, 2024 | markets.businessinsider.comGenprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingNovember 5, 2024 | prnewswire.comSee More Headlines GNPX Stock Analysis - Frequently Asked Questions How have GNPX shares performed this year? Genprex's stock was trading at $0.8516 at the beginning of 2025. Since then, GNPX stock has decreased by 1.6% and is now trading at $0.8376. View the best growth stocks for 2025 here. How were Genprex's earnings last quarter? Genprex, Inc. (NASDAQ:GNPX) released its quarterly earnings results on Friday, August, 9th. The company reported ($3.00) earnings per share for the quarter, missing the consensus estimate of ($2.30) by $0.70. When did Genprex's stock split? Shares of Genprex reverse split on the morning of Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Genprex? Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Genprex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genprex investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/09/2024Today1/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNPX CUSIPN/A CIK1595248 Webwww.genprex.com Phone(877) 774-4679FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+1,093.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-409.48% Return on Assets-269.17% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.99 per share Price / Book0.17Miscellaneous Outstanding Shares8,508,000Free Float7,787,000Market Cap$7.13 million OptionableNo Data Beta-1.30 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:GNPX) was last updated on 1/6/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.